Zhi Tong Cai Jing·2026-02-13 09:54Core Viewpoint - Fosun Pharma's subsidiary, Gismed (Wuhan) Pharmaceutical Co., Ltd., has received acceptance from the National Medical Products Administration for the drug registration application of Cisplatin Injection, which is intended for the treatment of metastatic testicular tumors, metastatic ovarian tumors, and advanced bladder cancer [1] Group 1: Drug Development and Financials - The drug is independently developed by the group and has seen a cumulative R&D investment of approximately RMB 4.69 million (unaudited) as of January 2026 [1] - According to the latest data from IQVIA CHPA, the sales revenue of Cisplatin Injection in mainland China (excluding Hong Kong, Macau, and Taiwan) is projected to be around RMB 165 million in 2024 [1]